Monoclonal antibody | |
---|---|
Type | Fab fragment |
Source | Human |
Target | Ticagrelor, AR-C124910XX (the active metabolite) [1] |
Clinical data | |
Other names | PB2452, MEDI2452 |
Routes of administration | Intravenous infusion |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
PubChem SID | |
DrugBank | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C2095H3240N560O674S12 |
Molar mass | 47440.93 g·mol−1 |
Bentracimab is a monoclonal antibody medication which has been shown in phase one and two clinical trials to function as a reversal agent for the anti–blood clotting drug ticagrelor (which acts as a P2Y12 inhibitor and is sold under the brand name Brilinta among others). [2] It is under investigation for use in major, life-threatening bleeding in patients being treated with ticagrelor. [3] [4] It is not commercially available.
Monoclonal antibody | |
---|---|
Type | Fab fragment |
Source | Human |
Target | Ticagrelor, AR-C124910XX (the active metabolite) [1] |
Clinical data | |
Other names | PB2452, MEDI2452 |
Routes of administration | Intravenous infusion |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
PubChem SID | |
DrugBank | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C2095H3240N560O674S12 |
Molar mass | 47440.93 g·mol−1 |
Bentracimab is a monoclonal antibody medication which has been shown in phase one and two clinical trials to function as a reversal agent for the anti–blood clotting drug ticagrelor (which acts as a P2Y12 inhibitor and is sold under the brand name Brilinta among others). [2] It is under investigation for use in major, life-threatening bleeding in patients being treated with ticagrelor. [3] [4] It is not commercially available.